Detalhe da pesquisa
1.
Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
HIV Clin Trials;
17(1): 38-47, 2016 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26728706
2.
Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz.
Curr HIV Res;
14(1): 61-70, 2016.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26531764
3.
Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
Infect Dis (Lond);
47(9): 625-36, 2015 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25875396
4.
Skeletal muscle toxicity in HIV-1-infected patients treated with a raltegravir-containing antiretroviral therapy: a cohort study.
AIDS Res Hum Retroviruses;
30(12): 1162-9, 2014 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25369244
5.
Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk.
AIDS Res Hum Retroviruses;
29(3): 547-56, 2013 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23098891